Literature DB >> 28890346

Hepatoprotective effects of Methyl ferulic acid on alcohol-induced liver oxidative injury in mice by inhibiting the NOX4/ROS-MAPK pathway.

Chen Li1, Li Li1, Cheng-Fang Yang1, Yu-Juan Zhong1, Dan Wu1, Lin Shi1, Li Chen1, Yong-Wen Li2.   

Abstract

AIMS: The present study aimed to investigate the hepatoprotective effects of Methyl ferulic acid (MFA) against oxidative stress and apoptosis as well as inflammation in mice with liver injury induced by alcohol and its underlying mechanisms.
METHODS: C57BL/6 mice were divided into a control group,a model group, and Methyl ferulic acid with high dosage (20 mg/kg), moderate dosage (10 mg/kg) and low dosage (5 mg/kg) groups. The general condition and organ index of each group were investigated. Histopathological analysis was performed to determine the degree of hepatic injury. Biochemical analyses of functional liver enzymes, lipid peroxidation enzymes and lipid content in each group. The levels of inflammatory cytokines were measured by enzyme-linked immunosorbent assay (ELISA). The mechanisms were investigated by detecting levels of NADPH Oxidase 4 (NOX4),p22phox, cytochrome P4502E1 (CYP2E1),Bax,B-cell lymphoma 2 (Bcl-2),cleaved-caspase 3 and 9 and phosphorylated extracellular regulated protein kinases(ERK),phosphorylated c-Jun N-terminal kinase (JNK), and phosphorylated p38 mitogen-activated protein kinase (MAPK) using real-time polymerase chain reaction (PCR) and Western blotting.
RESULTS: MFA treatment significantly decreased serum enzymatic activities of alanine aminotransferase (ALT) and aspartate aminotransaminase (AST). MFA markedly increased levels of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GSH-Px) and total antioxidative capacity (T-AOC), and reduced the concentration of malondialdehyde (MDA) and reactive oxygen species (ROS). Histopathological examination of livers showed that MFA reduced cytoplasmic vacuolisation necrosis and inflammatory cell infiltration in alcohol-treated mice. MFA treatment remarkably reduced the levels of trigyceride (TG), total cholesterol (TC) and low-density lipoprotein (LDL), decreasing the levels of high-density lipoprotein (HDL), alcohol dehydrogenase(ADL) and aldehyde dehydrogenase (ALDH). MFA treatment remarkably inhibited the expression of inflammatory factors tumour necrosis factor (TNF)-α, monocyte chemoattractant protein 1 (MCP-1), interleukin (IL)-1β and IL-6. MFA attenuated both mRNA and protein expression of NOX4,p22phox,CYP2E1,Bax/Bcl-2. In addition, MFA inhibited the activation of caspase 3 and 9 and downregulated the levels of p-JNK,p-p38 MAPK and p-ERK in liver.
CONCLUSION: MFA has a protective effect on alcohol-induced liver injury, which may be related to its antioxidant,anti-inflammatory,lipid-eliminating properties and its ability to regulate the NOX4/ROS-MAPK signalling pathway.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol; Liver injury; Methyl ferulic acid; Oxidative stress

Mesh:

Substances:

Year:  2017        PMID: 28890346     DOI: 10.1016/j.bbrc.2017.09.030

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Caffeic acid dimethyl ether alleviates alcohol-induced hepatic steatosis via microRNA-378b-mediated CaMKK2-AMPK pathway.

Authors:  Jun Lu; Yan Zhang; Ying-Zhao Wang; Yuan-Yuan Li; Rui Wang; Yu-Juan Zhong; Li Chen; Meng-Wei Song; Lin Shi; Li Li; Yong-Wen Li
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Transgenic overexpression of CTRP3 prevents alcohol-induced hepatic triglyceride accumulation.

Authors:  Greta Trogen; Joshua Bacon; Ying Li; Gary L Wright; Ashley Degroat; Kendra L Hagood; Zachary Warren; Allan Forsman; Aruna Kilaru; W Andrew Clark; Jonathan M Peterson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-05-15       Impact factor: 4.310

3.  Hepatoprotective effect of methyl ferulic acid against carbon tetrachloride-induced acute liver injury in rats.

Authors:  Chengfang Yang; Li Li; Zuheng Ma; Yujuan Zhong; Wenxiao Pang; Meili Xiong; Shuping Fang; Yongwen Li
Journal:  Exp Ther Med       Date:  2017-12-27       Impact factor: 2.447

4.  Anti-hepatofibrosis effect of Allium senescens in activated hepatic stellate cells and thioacetamide-induced fibrosis rat model.

Authors:  Gwang-Mo Shin; Sushruta Koppula; Yun-Jin Chae; Hyun-Su Kim; Jae-Dong Lee; Myong-Ki Kim; MinDong Song
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

Review 5.  Chemical Constituents, Pharmacologic Properties, and Clinical Applications of Bletilla striata.

Authors:  Delin Xu; Yinchi Pan; Jishuang Chen
Journal:  Front Pharmacol       Date:  2019-11-01       Impact factor: 5.810

6.  microRNA-378b regulates ethanol-induced hepatic steatosis by targeting CaMKK2 to mediate lipid metabolism.

Authors:  Ying-Zhao Wang; Jun Lu; Yuan-Yuan Li; Yu-Juan Zhong; Cheng-Fang Yang; Yan Zhang; Li-Hua Huang; Su-Mei Huang; Qi-Ran Li; Dan Wu; Meng-Wei Song; Lin Shi; Li Li; Yong-Wen Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Novel Insights into Alcoholic Liver Disease: Iron Overload, Iron Sensing and Hemolysis.

Authors:  Sebastian Mueller; Cheng Chen; Johannes Mueller; Shijin Wang
Journal:  J Transl Int Med       Date:  2022-07-10

8.  Effects of FM0807, a novel curcumin derivative, on lipopolysaccharide-induced inflammatory factor release via the ROS/JNK/p53 pathway in RAW264.7 cells.

Authors:  Yilong Wu; Zhiwei Liu; Weifang Wu; Su Lin; Nanwen Zhang; Honglin Wang; Shuangyu Tan; Peimin Lin; Xiaole Chen; Lixian Wu; Jianhua Xu
Journal:  Biosci Rep       Date:  2018-10-17       Impact factor: 3.840

9.  Investigating RNA expression profiles altered by nicotinamide mononucleotide therapy in a chronic model of alcoholic liver disease.

Authors:  Mohammed A Assiri; Hadi R Ali; John O Marentette; Youngho Yun; Juan Liu; Matthew D Hirschey; Laura M Saba; Peter S Harris; Kristofer S Fritz
Journal:  Hum Genomics       Date:  2019-12-10       Impact factor: 4.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.